Interview with Dr. Michael Young, pre-clinical investigator with ReNeuron’s hRPC retinal technology
Interview with Dr. Eric Pierce, Principal Investigator on ReNeuron’s Phase I/II clinical trial for Retinitis Pigmentosa
Pro-Active Investors : ReNeuron making good progress in clinical trials, says CFO
BBC News reports on patient treated in ReNeuron Phase II stroke clinical trial

A great-grandfather becomes one of the first in the UK to be treated for a stroke, using stem cells.

Watch video: http://www.bbc.co.uk/news/health-36450628.

CFO gives interview at Proactive Investors after ReNeuron announces first patient treated in US Phase I/II clinical trial in retinitis pigmentosa

It is hoped that ReNeuron’s treatment will “at the very least” arrest the deterioration in eyesight caused by the disease and in the best case restore sight.

CFO gives interview at Proactive Investors after £68.4 million placing

ReNeuron was one of the best performers on the AIM market after a successful placing which had the backing of star fund manager, Neil Woodford.

CFO gives interview at IG

After fund manager Neil Woodford bought a 20% stake in ReNeuron, CFO Michael Hunt discusses the opportunities for the company.

Multimedia Interview with Michael Hunt, ReNeuron Chief Executive Officer – 30th August 2013

Visit page: http://reut.rs/14J5zqc